MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting
MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting
The highlights of presentation are as follows:
演示的亮點如下：
The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment.
MN-166和TMZ組合治療的主要終點是安全性和耐受性，以及組合治療的療效。
The combination of Temozolomide (TMZ) and MN-166 was safe and well tolerated. No unexpected adverse effects were observed in both new GBM and recurrent GBM patients. Most reported adverse events were Lymphopenia, Leukopenia, Thrombocytopenia and Neutropenia.
Temozolomide（TMZ）和MN-166的組合治療是安全和耐受的。在新的GBM和複發性GBM患者中均未觀察到意外的不良反應。大多數報告的不良事件是淋巴細胞減少症、白細胞減少症、血小板減少症和中性粒細胞減少症。
Preclinical data has shown improved survival with the combination of Ibudilast and PD-1 or PD-L1 antibody therapy compared to treatment with ibudilast alone or PD-1/PD-L1 antibody alone, suggesting a potential promising therapeutic benefit of this combination.
臨床前數據顯示，與僅使用ibudilast或PD-1/PD-L1抗體單獨治療相比，使用Ibudilast和PD-1或PD-L1抗體療法的組合治療可以改善生存率，表明該組合可能具有潛在的治療益處。